Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Diagnostics › Molecular Diagnostics › AstraZeneca's Lynparza Gives Survival Boost as Maintenance in Relapsed BRCA-Mutated Ovarian Cancer

AstraZeneca's Lynparza Gives Survival Boost as Maintenance in Relapsed BRCA-Mutated Ovarian Cancer

May 14, 2020
|
Andrea Anderson

NEW YORK – The PARP inhibitor olaparib (AstraZeneca/Merck's Lynparza) appears to extend overall survival when used as a post-chemotherapy maintenance treatment in women with advanced ovarian cancer who carry a BRCA1 or BRCA2 mutation, according to a final survival analysis from the Phase III SOLO2/ENGOT-ov21 trial.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

May
27
Featured Webinar

Identifying Molecular Drivers of Cancer via Comprehensive Sequencing of a Large Cohort with Matched Germline and Clinical Data

Sponsored by
Discovery Life Sciences

M2Gen’s Oncology Research Information Exchange Network (ORIEN) Avatar Research Program collects and studies consented cancer patients’ biospecimens and companion clinical information for the development of improved oncology treatments. 

What's Popular?

In Cancer

  1. Janssen Antibody Produces Durable Responses in Lung Cancer Subset With Poor Prognosis

    Premium

  2. Opdivo, Yervoy Another First-Line Option in NSCLC, Though Maybe Not Some Oncologists' Top Choice

    Premium

  3. Roche's Flatiron Health, Foundation Medicine, Genentech Launch Clinico-Genomic Lung Cancer Study

  4. FDA Approves Lynparza With Myriad, Foundation Med CDx Tests in HRR-Mutated Prostate Cancer

  5. Apollomics Advances Phase I/II SPARTA Trial for C-MET Inhibitor in MET-Altered Tumors

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.